TAC 363
TAC 363 is a selective tachykinin NK-2 receptor antagonist. TAC 363 shows a rightward shift in the contractile response curve induced by Neurokinin A with a pA2 of 9.82. TAC 363 has a weak antagonistic effect on NK-1 receptors. TAC 363 can inhibit Neurokinin A-induced bronchoconstriction in guinea pigs with an ED50 of 0.3 mg/kg. TAC 363 can be used for the research of bronchial asthma[1].
Product Specifications
CAS Number
172081-08-2
UNSPSC
12352005
Target
Neurokinin Receptor
Related Pathways
GPCR/G Protein; Neuronal Signaling
Field of Research
Inflammation/Immunology
Smiles
O=C(NCCOCC1=CC=CC=C1)N(CC2=CC=CC=C2)NC([C@@H](NC([C@H](CCC(N)=O)NC(NC(C)(C)C)=O)=O)CC3=CNC4=CC=CC=C34)=O
Molecular Formula
C38H48N8O6
Molecular Weight
712.84
References & Citations
[1]Higashide Y, et al. [Pharmacological profiles of a novel tachykinin NK-2 receptor antagonist, TAC-363]. Yakugaku Zasshi. 1996 Nov;116 (11) :884-91. Japanese.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
NK2R
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC680017-100 1x 100 µL
Ep-CAM / CD326 (VU-1D9), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC681081-500 1x 500 µL
CD45RO (190-2F2.5), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC681081-100 1x 100 µL
CD45RO (190-2F2.5), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 